Parbraze 150mg Tablet

About

Ibandronate is a potent nitrogen-containing bisphosphonate that acts primarily on bone tissue to inhibit osteoclast-mediated bone resorption. It achieves this by binding to hydroxyapatite crystals in the bone matrix and being internalized by osteoclasts, where it interferes with the mevalonate pathway, leading to osteoclast dysfunction and apoptosis. This selective action helps to increase bone mineral density and significantly reduce the incidence of vertebral fractures in postmenopausal women with osteoporosis. Its long duration of action allows for convenient once-monthly oral administration, which enhances patient adherence and provides sustained therapeutic benefits. This mechanism helps to restore the balance between bone formation and resorption, crucial for maintaining skeletal integrity and preventing fragility fractures.

Uses

• Treatment of postmenopausal osteoporosis.
• Prevention of vertebral fractures in postmenopausal women.
• Increase bone mineral density in osteoporotic patients.
• Management of bone metastases to reduce skeletal-related events (though 150mg is typically for osteoporosis).

Directions For Use

Take one tablet orally once a month, on the same date each month, at least 60 minutes before the first food or drink (other than plain water) of the day.

Benefits

• Increases bone mineral density.
• Reduces the risk of vertebral fractures.
• Convenient once-monthly dosing.
• Helps maintain bone strength.
• Effective in postmenopausal osteoporosis.
• Improves long-term bone health.

Side Effects

• Esophageal irritation or ulceration
• Dyspepsia
• Abdominal pain
• Nausea
• Diarrhea
• Musculoskeletal pain
• Headache
• Flu-like symptoms
• Dizziness
• Rash
• Jaw osteonecrosis (rare)
• Atypical femoral fractures (rare)

Safety Measures

• Alcohol - Excessive alcohol intake can contribute to bone loss and may increase the risk of gastrointestinal irritation. It is advisable to limit alcohol consumption.
• Pregnancy - Contraindicated in pregnancy due to potential fetal harm. Not for use in women of childbearing potential unless effective contraception is used.
• Breastfeeding - It is unknown if ibandronate is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended.
• Liver - No dose adjustment is typically required in patients with liver impairment.
• Kidney - Contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min). Use with caution in moderate impairment.
• Lung - No specific contraindications or precautions related to lung conditions are generally noted for this medication.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.